( lysorbate 80 on susceptibility of gram-...)Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics,Health

lysorbate 80 on susceptibility of gram-positive bacteria to oritavancin (ECCMID/ICC07-P 827) Following initial observations that P80 reduced ORI MICs for S. aureus and E. faecalis but not for S. pneumoniae, this study examined the effect of P80 on ORI MICs for 301 clinical strains of bacteria from these three genera, in comparison with VAN and TEI. Researchers observed significant reductions in ORI MICs for enterococci and staphylococci with P80 (16- to 32-fold) while P80 had little to no effect on MICs for TEI and VAN. ORI MICs were unchanged with and without P80 for streptococci, which may be related to the inclusion of LHB in the culture medium. -- Efficacy of oritavancin in a mouse model of Streptococcus pneumoniae pneumonia (ECCMID/ICC07-P 1781) Streptococcus pneumoniae is one of the leading causes of community- acquired bacterial infections and can cause a number of infections including pneumonia, acute sinusitis, otitis media, bacteremia and meningitis(2). S. pneumoniae is a leading cause of morbidity and mortality in the United States, resulting each year in an estimated 500,000 cases of pneumonia. S. pneumoniae bacteria have been uniformly susceptible to penicillin in the past; however, as multi-drug resistant strains become more prevalent, first-line therapies such as penicillin are not always effective, and advanced agents are being explored to prevent complications or mortality. In Vivo Researchers tested the in vivo activity of ORI against penicillin- sensitive S. pneumoniae (PSSP) pneumonia in a mouse model, compared with daptomycin (DAP) and ceftriaxone (CTX). During the study, immunocompetent mice were exposed intranasally to one million colony-forming units (CFU) of PSSP. Doses of ORI (32 mg/kg
'"/>




Page: 1 2 3 4 5 6
Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS